Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Global study of bevacizumab added to carboplatin and paclitaxel as front-line treatment for epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma
2010-019525-34Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of bevacizumab in epithelial ovarian cancer (EOC), fallopian tube cancer (PFTC), primary peritoneal cancer (PPC) and 1 more, sponsored by Roche. Primary endpoints: Safety of bevacizumab added to carboplatin and paclitaxel and Efficacy of bevacizumab added to carboplatin and paclitaxel. Started Aug 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
epithelial ovarian cancer (EOC)fallopian tube cancer (PFTC)primary peritoneal cancer (PPC)ovarian cancer
Beyond the preview
Go deeper on 2010-019525-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019525-34.